European Medicines Agency (EMA)

Investment thesis

The EMA is the EU's centralised regulatory authority for medicines, not a grant-making body. It does not provide funding, equity, or grants to companies. Its role is to evaluate scientific data to authorise medicines for the EU market, ensuring safety, efficacy, and quality. [1] It operates on fees paid by industry for regulatory services, not public grants for innovation. [1] The agency's mandate is public health protection through scientific assessment, not commercial development. [1] It supports innovation through regulatory pathways like PRIME and orphan drug designation, which accelerate access but do not provide capital. [2] Founders should look to EU framework programmes (e.g., Horizon Europe) or national agencies for funding, not the EMA. [1]

Value add

Regulatory certainty through scientific advice and CHMP opinions. [2] Potential for accelerated assessment or PRIME designation, reducing time to market. [2] Credibility of EU-wide market authorisation. [1] Fit verdict: Not applicable for funding. Founder diligence script: 1. Does my product require centralised authorisation? 2. What regulatory pathways (PRIME, orphan) am I eligible for? 3. What are the fee structures and reductions available? 4. When should I seek scientific advice? 5. What are the specific data requirements for my product type?

Portfolio focus

The EMA does not have a portfolio of funded projects. [1] Its 'portfolio' consists of authorised medicines, which include a wide range of therapeutic areas. [2] Recent approvals include treatments for psoriasis, age-related macular degeneration, and weight loss. [2] The agency's work focuses on ensuring the safety and efficacy of all medicines on the EU market. [1]